CAJ | 학술논문

目的：观察应用卡培他滨维持治疗转移性乳腺癌患者的疗效及不良反应。方法对一线化疗疾病获得控制的晚期转移性乳腺癌患者，给予卡培他滨单药维持化疗直至疾病进展，具体给药方案：1000 mg／m2口服，每天2次，第1～14天持续给药，每3周重复。结果30例转移性乳腺癌患者共完成维持化疗124个周期，中位无进展生存时间（MPFS）为6．8个月（2．9～19．0个月）。主要不良反应为手足综合征和白细胞减少，但均可耐受。结论转移性乳腺癌患者给予卡培他滨维持治疗，可明显延长患者的无进展生存期，同时不良反应均可耐受。
목적：관찰응용잡배타빈유지치료전이성유선암환자적료효급불량반응。방법대일선화료질병획득공제적만기전이성유선암환자，급여잡배타빈단약유지화료직지질병진전，구체급약방안：1000 mg／m2구복，매천2차，제1～14천지속급약，매3주중복。결과30례전이성유선암환자공완성유지화료124개주기，중위무진전생존시간（MPFS）위6．8개월（2．9～19．0개월）。주요불량반응위수족종합정화백세포감소，단균가내수。결론전이성유선암환자급여잡배타빈유지치료，가명현연장환자적무진전생존기，동시불량반응균가내수。
Objective To observe the efficacy and toxicities of maintenance chemotherapy with capecitabine for meta -static breast cancer ( MBC) .Methods Advanced metastatic breast cancer patients who achieved disease control with first -line treatment received capecitabine as maintenance chemotherapy until disease progression .Capecitabine was administered at a dose of 1 000 mg/m2 ,twice daily,for 14 days,followed by a 7-day rest period,every 3 weeks.Results 30 patients finished 124 cycles of maintenance chemotherapy .Median progression free survival time was 6.8 months (2.9~19.0 months).The main side effects were hand-foot syndrome and leucopenia which were tolerable .Conclusion Maintenance chemotherapy with capecitabine for metastatic breast cancer can extend progression free survival time with tolerable side effects .